GO:0140329 lysophospholipid translocation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140329 lysophospholipid translocation is the biological process that moves a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet.
• The process is essential for lysosomal lipid homeostasis, membrane remodeling, and mTOR-regulated metabolic signaling [1, 4].
• SPNS1 is a principal lysophospholipid transporter; loss of SPNS1 causes lysolipid accumulation and lysosomal storage disease in mouse models.
• SPNS2, a related SPNS-family exporter, transports sphingosine-1-phosphate (S1P) and has been structurally and functionally characterized [2, 5].
• Human SPNS1 variants cause a multiorgan disease that links lysophospholipid transport to mTOR-regulated lipid homeostasis.
• Pharmacological inhibition of S1P transporters such as SPNS2 is an active area of probe and drug development.
Description
Lysophospholipid translocation (GO:0140329) is defined as the movement of a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet. Lysophospholipids are glycerophospholipid or sphingolipid derivatives that carry a single acyl chain and are generated by phospholipase-mediated hydrolysis or by deacylation reactions; because they are amphipathic, their transbilayer distribution is controlled by dedicated transporters rather than by passive diffusion alone. The process is therefore a distinct biological process rather than a generic lipid-transfer activity, and it is required for normal membrane lipid asymmetry and organelle function [1, 4]. Research interest in GO:0140329 has grown because mutations in the transporter SPNS1 cause lysolipid accumulation and a lysosomal storage phenotype in mouse models, and because human SPNS1 variants produce a multiorgan disease implicating lysophospholipid transport in mTOR-regulated lipid homeostasis [1, 4]. The related SPNS-family protein SPNS2 exports sphingosine-1-phosphate (S1P), a signaling lysophospholipid, and its transport mechanism has been resolved structurally [2, 5]. These findings place lysophospholipid translocation at the intersection of lysosomal biology, lipid signaling, and metabolic disease. For researchers, GO:0140329 provides a precise annotation target for studies of membrane lipid asymmetry, lysosomal catabolism, and lipid-mediated signal transduction. Because the process is carried out by membrane-embedded transporters, it is amenable to genetic perturbation by CRISPR knockout, point mutation, and knock-in strategies, as well as to biochemical transport assays and lipidomics [1, 4, 5].
lysophospholipid translocation At A Glance
| GO ID | GO:0140329 |
|---|---|
| GO term | lysophospholipid translocation |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Movement of a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet |
| Representative transporters | SPNS1, SPNS2 (SPNS family) [1, 2, 4, 5] |
| Substrate class | Lysophospholipids including lysophosphatidylcholine and sphingosine-1-phosphate [2, 4, 5] |
| Associated disease | Multiorgan disease with lysosomal storage features linked to SPNS1 variants [1, 4] |
| Research methods | CRISPR knockout, lipidomics, transport assays, structural biology [1, 2, 4, 5] |
What Is GO:0140329?
In plain terms, lysophospholipid translocation is the flipping or transfer of a lysophospholipid molecule across a membrane so that it moves from the leaflet where it was produced or delivered to the opposite leaflet. The QuickGO definition states that GO:0140329 describes the movement of a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet. This is a directional, protein-assisted process that maintains the asymmetric distribution of lysolipids between the two faces of a membrane and supports downstream lipid signaling and catabolism [1, 4].
Why Is lysophospholipid translocation Important in Cell Biology?
Lysophospholipid translocation matters because lysophospholipids are not merely metabolic intermediates; they are signaling molecules and membrane-perturbing agents whose accumulation is cytotoxic. The process maintains the transbilayer distribution of these lipids and thereby protects lysosomal and plasma membranes from detergent-like stress. Genetic loss of SPNS1 causes lysolipid accumulation and lysosomal storage disease in mice, and human SPNS1 variants cause a multiorgan disorder tied to mTOR-regulated lipid homeostasis, demonstrating that GO:0140329 is required for organismal health [1, 4]. In parallel, SPNS2-mediated S1P transport controls a lipid-signaling axis that influences endothelial biology and immune cell trafficking, and its inhibition is being explored pharmacologically [2, 5, 7, 8].
• Maintains lysophospholipid asymmetry across membrane bilayers, preventing detergent-like membrane damage [1, 4].
• Supports lysosomal lipid catabolism and homeostasis; SPNS1 loss causes lysosomal storage disease in mice.
• Links lysophospholipid transport to mTOR-regulated lipid homeostasis in human disease.
• Enables S1P secretion by SPNS2, which controls a lipid-signaling axis in endothelium and immunity [2, 5, 7].
• Provides a druggable node; imidazole-based SPNS2 inhibitors have been developed.
• Connects to cholesterol transport and HDL biology through S1P signaling and E-Syt1.
• Is relevant to cancer biology via S1P/YAP-mediated angiogenesis and tumor immune escape.
• Offers a defined annotation target for lipidomics and membrane biology studies [1, 4].
• Can be perturbed precisely with CRISPR knockout, point mutation, and knock-in models [1, 4, 5].
• Informs therapeutic strategies for lysosomal storage disorders and lipid-driven diseases [1, 4].
What Happens During lysophospholipid translocation?
Substrate recognition and membrane insertion
In simple terms: The transporter first finds and binds its lipid cargo at the membrane.
Lysophospholipid translocation begins when a membrane-embedded transporter recognizes a lysophospholipid substrate within one leaflet of the bilayer. SPNS-family proteins such as SPNS1 and SPNS2 are polytopic membrane proteins that bind lysolipid or S1P substrates and position them for transfer [1, 2, 4, 5]. Structural and functional studies of SPNS2 show that substrate recognition is coupled to the transporter's conformational cycle, providing the molecular basis for lipid selectivity [2, 5].
Transbilayer movement
In simple terms: The cargo is flipped across the membrane to the other side.
Once bound, the lysophospholipid is moved from the donor leaflet to the opposite leaflet. This step is the defining event of GO:0140329 and is mediated by conformational changes in the transporter rather than by free diffusion [1, 2, 4, 5]. For SPNS2, structural analyses have captured distinct states that illuminate how S1P is translocated across the bilayer [2, 5].
Release and downstream utilization
In simple terms: After flipping, the lipid is released where it is needed.
Following translocation, the lysophospholipid is released into the acceptor leaflet or lumen, where it can be catabolized, sensed, or secreted. In the lysosome, SPNS1-dependent transport supports lipid homeostasis, and its loss leads to lysolipid accumulation and lysosomal storage pathology [1, 4]. For SPNS2, release of S1P enables autocrine and paracrine signaling that influences endothelial and immune cell behavior [2, 5, 7].
Coupling to lipid homeostasis and signaling
In simple terms: The flipped lipid feeds into broader metabolic and signaling networks.
Translocated lysophospholipids are integrated into lipid homeostatic circuits. Human SPNS1 variants link lysophospholipid transport to mTOR-regulated lipid homeostasis, indicating that the process is coupled to nutrient-sensing pathways. S1P exported by SPNS2 participates in signaling that intersects with cholesterol transport and angiogenesis, including S1P/YAP-mediated endothelial responses [6, 7].
Regulation and inhibition
In simple terms: The process can be tuned or blocked by regulators and inhibitors.
Lysophospholipid translocation is subject to regulation and can be pharmacologically inhibited. Imidazole-based compounds inhibit the S1P transporter SPNS2, demonstrating that transporter activity is a tractable target. Transport and inhibition studies of SPNS2 provide a framework for understanding how small molecules modulate lysophospholipid translocation [5, 8].
Key Genes Involved in GO:0140329 lysophospholipid translocation
The genes most directly implicated in lysophospholipid translocation (GO:0140329) are the SPNS-family transporters and their associated lipid-handling and signaling partners.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPNS1 | Lysophospholipid transporter required for lysosomal lipid homeostasis [1, 4] | Loss causes lysolipid accumulation and lysosomal storage disease; human variants cause multiorgan disease [1, 4] |
| SPNS2 | S1P exporter of the SPNS family [2, 5] | Structurally characterized transporter; target of imidazole-based inhibitors [2, 5, 8] |
| S1PR1 | S1P receptor mediating downstream signaling | Links translocated S1P to endothelial and immune responses |
| YAP | Transcriptional effector downstream of S1P signaling | Mediates S1P/YAP-driven angiogenesis and tumor immune escape |
| E-Syt1 | Extended synaptotagmin involved in lipid transfer | S1P signaling activates E-Syt1 to facilitate HDL-derived cholesterol transport |
| mTOR | Nutrient-sensing kinase regulating lipid homeostasis | Couples lysophospholipid transport to metabolic regulation |
| ATP13A2 | Lysosomal polyamine transporter influencing lysosomal pH | Loss alters lysosomal hydrolase-lipid interactions relevant to lysosomal lipid biology |
| GBA | Lysosomal β-glucocerebrosidase | Its activity is impaired by altered lysosomal pH and lipid interactions |
| ABCA1 | Cholesterol and phospholipid transporter | Relevant to HDL-derived cholesterol transport linked to S1P signaling |
| SPNS3 | SPNS-family transporter paralog | Candidate lysophospholipid transporter for comparative studies |
| MFSD2A | Lysolipid transporter family member | Provides comparative context for lysolipid transport mechanisms |
| PLA2G | Phospholipase generating lysophospholipids | Source of lysophospholipid substrates for translocation |
| LCAT | Enzyme acting on HDL lipids | Relevant to HDL lipid metabolism intersecting with S1P signaling |
| SGPL1 | S1P-degrading enzyme | Controls S1P availability for SPNS2-mediated export |
| SPHK1 | Sphingosine kinase producing S1P | Generates the SPNS2 substrate S1P |
| SPHK2 | Sphingosine kinase producing S1P | Contributes to intracellular S1P pools |
| OX40 | Costimulatory receptor on endothelial cells | Endothelial OX40 activation promotes S1P/YAP-mediated angiogenesis |
How Is lysophospholipid translocation Regulated?
Lysophospholipid translocation is regulated at multiple levels. Human SPNS1 variants link the process to mTOR-regulated lipid homeostasis, indicating that nutrient-sensing signaling influences lysophospholipid transport and its downstream consequences. The activity of SPNS2 can be modulated pharmacologically, as imidazole-based inhibitors block this S1P transporter. In addition, S1P signaling downstream of translocation activates E-Syt1 to facilitate HDL-derived cholesterol transport, showing that the process is embedded in a regulated lipid-transfer network. Lysosomal pH and electrostatic hydrolase-lipid interactions also influence lysosomal lipid handling, providing an additional layer of regulation relevant to lysophospholipid biology.
lysophospholipid translocation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPNS1 | Multiorgan disease with lysosomal storage features [1, 4] | Spns1 knockout and point-mutation knock-in mouse or cell models [1, 4] |
| SPNS2 | S1P signaling in endothelium and immunity [2, 5, 7] | SPNS2 knockout and tagged knock-in cells for transport assays [2, 5] |
| OX40 | S1P/YAP-mediated angiogenesis and tumor immune escape | Endothelial OX40 overexpression and knockout models |
| E-Syt1 | HDL-derived cholesterol transport downstream of S1P | E-Syt1 knockout and overexpression cell models |
| ATP13A2 | Lysosomal pH and hydrolase-lipid interactions | ATP13A2 knockout cells with lysosomal functional readouts |
SPNS1-related multiorgan disease and lysosomal storage
Human SPNS1 variants cause a multiorgan disease and implicate lysophospholipid transport as critical for mTOR-regulated lipid homeostasis. In mouse models, lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease, establishing a direct causal link between defective lysophospholipid translocation and lysosomal pathology. These findings identify GO:0140329 as a disease-relevant process in inherited metabolic disorders.
S1P signaling, angiogenesis, and tumor immune escape
SPNS2-mediated S1P export supports a signaling axis that influences endothelial biology. Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis, linking lysophospholipid translocation to cancer immune evasion. S1P signaling also activates E-Syt1 to facilitate HDL-derived cholesterol transport, connecting translocated lysophospholipids to cholesterol metabolism.
Lysosomal hydrolase dysfunction and lipid interactions
Lysosomal lipid handling is sensitive to pH and electrostatic interactions. Loss of ATP13A2 causes lysosomal polyamine storage that impairs β-glucocerebrosidase via altered lysosomal pH and electrostatic hydrolase-lipid interactions, illustrating how lysosomal lipid and hydrolase biology intersect with lysophospholipid-related pathways. This context is relevant to understanding how defective lysophospholipid translocation may compound lysosomal dysfunction [1, 4].
From lysophospholipid translocation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SPNS1 cause lysolipid accumulation? | SPNS1 knockout cells and mice with lipidomics [1, 4] |
| How do disease-associated SPNS1 variants affect transport? | SPNS1 point-mutation knock-in cell lines |
| What is the substrate specificity of SPNS2? | SPNS2 knockout with tagged knock-in for transport assays [2, 5] |
| Can SPNS2 inhibitors block S1P export? | SPNS2-expressing cells treated with imidazole inhibitors |
| How does S1P signaling affect cholesterol transport? | E-Syt1 knockout and overexpression models |
| Does endothelial OX40 drive S1P/YAP angiogenesis? | Endothelial OX40 overexpression and knockout models |
How to Study the lysophospholipid translocation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Targeted lipidomics | Lysolipid species abundance | Detecting lysolipid accumulation in SPNS1 models [1, 4] |
| Fluorescent lipid transport assay | Transbilayer movement of lysophospholipids | Measuring transporter activity in cells [2, 5] |
| CRISPR knockout | Loss-of-function phenotype | Testing causal role of SPNS1/SPNS2 [1, 4] |
| Point-mutation knock-in | Effect of disease variants | Modeling human SPNS1 variants |
| Structural biology (cryo-EM) | Transporter conformational states | Understanding SPNS2 transport mechanism [2, 5] |
| Inhibitor profiling | Small-molecule blockade of transport | Developing SPNS2 inhibitors |
| Signaling immunoblotting | YAP and downstream pathway activity | Linking S1P to angiogenesis |
| Lysosomal function assays | pH and hydrolase activity | Assessing lysosomal lipid dysfunction |
Lipidomics and lysolipid quantification
Mass-spectrometry-based lipidomics is central to studying lysophospholipid translocation because it directly measures lysolipid species that accumulate when transport is impaired. Lack of SPNS1 results in accumulation of lysolipids, which can be quantified in cells and tissues by targeted lipidomics [1, 4]. This approach provides a functional readout for CRISPR perturbations of transporter genes.
Transport assays and structural biology
Direct transport assays using fluorescent or radiolabeled lysophospholipid substrates allow measurement of transbilayer movement. Structural and functional studies of SPNS2 have defined its transport mechanism and provided templates for inhibitor design [2, 5]. Transport and inhibition studies further show how small molecules modulate SPNS2 activity [5, 8].
CRISPR-based genetic perturbation
CRISPR knockout, point mutation, and knock-in strategies enable causal testing of transporter genes in lysophospholipid translocation. SPNS1 knockout models have been used to demonstrate lysolipid accumulation and lysosomal storage disease [1, 4], while SPNS2 models support structural and functional interrogation of S1P export [2, 5].
Signaling and imaging readouts
Downstream signaling can be monitored with phospho-protein immunoblotting, reporter assays, and imaging. S1P/YAP-mediated angiogenesis and E-Syt1-dependent cholesterol transport are examples of readouts that connect lysophospholipid translocation to cellular phenotypes [6, 7]. Lysosomal pH and hydrolase activity assays provide complementary functional endpoints.
How CRISPR Can Be Used to Study GO:0140329 lysophospholipid translocation
Knockout
CRISPR knockout of SPNS1 or SPNS2 provides a clean loss-of-function background to test the requirement for lysophospholipid translocation. SPNS1 knockout models have been used to show lysolipid accumulation and lysosomal storage disease in mice [1, 4], and SPNS2 knockout supports studies of S1P export and signaling [2, 5].
Point Mutation
Point-mutation knock-in allows modeling of disease-associated variants. Human SPNS1 variants cause multiorgan disease, and introducing these variants into cell or animal models enables assessment of their effects on lysophospholipid transport and mTOR-regulated lipid homeostasis.
Knock-in
Tagged knock-in of SPNS1 or SPNS2 enables localization, interaction, and transport studies in a native genomic context. Such models complement structural work on SPNS2 and support functional assays of lysophospholipid translocation [2, 5].
Overexpression
Overexpression of SPNS-family transporters or signaling partners such as OX40 and E-Syt1 can amplify pathway output for biochemical and imaging assays. Endothelial OX40 overexpression has been used to study S1P/YAP-mediated angiogenesis, and E-Syt1 models probe S1P-dependent cholesterol transport [6, 7].
How EDITGENE Supports lysophospholipid translocation Research
Researchers studying lysophospholipid translocation-related genes often need to determine whether a candidate gene is causally involved in lysolipid transport, lysosomal homeostasis, or S1P signaling. EDITGENE provides publication-grade CRISPR cell models and screening services that let teams move from candidate gene to validated mechanism with reproducible, sequence-verified reagents.
Contact EDITGENE today to design your custom CRISPR model for lysophospholipid translocation research.
Frequently Asked Questions About lysophospholipid translocation
What is lysophospholipid translocation?
Lysophospholipid translocation (GO:0140329) is the movement of a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet, a process mediated by membrane transporters such as SPNS1 and SPNS2 [1, 2, 4, 5].
What genes are involved in lysophospholipid translocation?
Key genes include SPNS1, which supports lysosomal lipid homeostasis, and SPNS2, which exports sphingosine-1-phosphate; downstream signaling involves S1PR1, YAP, E-Syt1, and mTOR [1, 2, 4, 5, 6, 7].
Why is lysophospholipid translocation important for cells?
It maintains lysophospholipid asymmetry, prevents membrane damage, supports lysosomal catabolism, and enables lipid signaling; its loss causes lysolipid accumulation and lysosomal storage disease [1, 4].
What happens when SPNS1 is lost?
Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models, and human SPNS1 variants cause a multiorgan disease linked to mTOR-regulated lipid homeostasis [1, 4].
How is SPNS2 related to lysophospholipid translocation?
SPNS2 is an SPNS-family transporter that exports sphingosine-1-phosphate, and its transport mechanism and inhibition have been characterized structurally and functionally [2, 5, 8].
Can lysophospholipid translocation be inhibited pharmacologically?
Yes, imidazole-based inhibitors of the S1P transporter SPNS2 have been developed, showing that transporter activity can be blocked by small molecules.
What diseases are linked to defective lysophospholipid transport?
Defects are linked to lysosomal storage disease and a multiorgan disorder caused by SPNS1 variants, as well as S1P-driven angiogenesis and tumor immune escape [1, 4, 7].
How do researchers study lysophospholipid translocation?
Common methods include targeted lipidomics, fluorescent lipid transport assays, CRISPR knockout and knock-in models, structural biology, and signaling readouts [1, 2, 4, 5].
What is the role of mTOR in lysophospholipid transport?
Human SPNS1 variants implicate lysophospholipid transport as critical for mTOR-regulated lipid homeostasis, linking the process to nutrient-sensing pathways.
How does S1P signaling connect to cholesterol transport?
Sphingosine-1-phosphate signaling activates E-Syt1 to facilitate HDL-derived cholesterol transport, connecting lysophospholipid translocation to cholesterol metabolism.
Conclusion
Lysophospholipid translocation (GO:0140329) is a defined biological process that moves lysophospholipids across membrane leaflets, and it is essential for lysosomal lipid homeostasis, membrane integrity, and lipid signaling. The SPNS-family transporters SPNS1 and SPNS2 are central to this process, and their dysfunction is linked to lysosomal storage disease, multiorgan disease, and S1P-driven cancer biology [1, 2, 4, 5, 7]. Because the process is genetically tractable, CRISPR knockout, point-mutation knock-in, and overexpression models are powerful tools for dissecting mechanism and disease relevance. EDITGENE supports these efforts with validated cell models, library screening, and bioinformatics tailored to lysophospholipid translocation research [1, 4, 5].
References
- 1. He M et al.. 2025. SPNS1 variants cause multiorgan disease and implicate lysophospholipid transport as critical for mTOR-regulated lipid homeostasis.. J Clin Invest 135(17) PMID: 40608416
- 2. Chen H et al.. 2023. Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate.. Cell 186(12):2644-2655.e16 PMID: 37224812
- 3. Samaddar M et al.. 2025. Lysosomal polyamine storage upon ATP13A2 loss impairs β-glucocerebrosidase via altered lysosomal pH and electrostatic hydrolase-lipid interactions.. Cell Rep 44(9):116179 PMID: 40848257
- 4. Ha HT et al.. 2024. Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models.. JCI Insight 9(8) PMID: 38451736
- 5. Li HZ et al.. 2025. Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2.. Nat Commun 16(1):721 PMID: 39820269
- 6. Xu Z et al.. 2025. Sphingosine-1-phosphate signalling activates E-Syt1 to facilitate HDL-derived cholesterol transport.. Nat Cell Biol 27(6):918-930 PMID: 40437229
- 7. He B et al.. 2025. Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis.. J Clin Invest 135(5) PMID: 40026246
- 8. Shrader CW et al.. 2023. Imidazole-based sphingosine-1-phosphate transporter Spns2 inhibitors.. Bioorg Med Chem Lett 96:129516 PMID: 37832799
